PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Naphazoline→

Naphazoline PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
835-31-4
Molecular formula
C14H14N2
Molecular weight
210.2744 g/mol
Drug class
Imidazoline alpha-adrenergic receptor agonisttopical vasoconstrictor
Mechanism of action
Stimulates alpha-adrenergic receptors in vascular smooth muscle, causing local vasoconstriction and reducing conjunctival hyperaemia or nasal mucosal oedema. Repeated use may cause rebound congestion.
Indications / reported uses
  • Temporary relief of minor ocular redness due to minor eye irritation in authorised ophthalmic formulations
  • Temporary relief of nasal congestion in authorised intranasal formulations; prolonged or excessive use can cause rebound congestion

Sources: US DailyMed — Naphazoline ophthalmic products · US eCFR — Ophthalmic vasoconstrictor drug products · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Naphazoline PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Naphazoline Permitted Daily Exposure (PDE) report (the Naphazoline PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Naphazoline Occupational Exposure Limit (OEL) report (the Naphazoline OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.